What does TZD stand for?

Both the drugs belong to a class of drugs called thiazolidinediones and are widely used for the treatment of type 2 diabetes.

Thiazolidinediones are a relatively new diabetes type 2 treatment drug, that comes in two distinct forms, rosiglitazone and pioglitazone.

We then demonstrate that: i) RORalpha, and specifically its RORalpha1 isoform, is expressed in DU 145 cells; ii) activation of RORalpha, by means of the thiazolidinedione derivative CGP 52,608 (the synthetic RORalpha activator), significantly reduces 5-LOX expression, both at mRNA (as evaluated by comparative RT-PCR) and at protein (as investigated by Western blot analysis) level (this was confirmed by the reduced activity of 5-LOX in CGP 52,608 treated cells); and iii) the treatment of DU 145 cells with CGP 52,608 completely abrogated the proliferative action of both LA and AA.

Subsequent chapters address such topics as inflammatory markers in cardiovascular disease, dietary prescriptions, pharmacological therapy, the effects of thiazolidinediones, high-density lipoproteins, the management of hypertriglyceridemia, reducing atherosclerotic coronary heart disease risk, cardiovascular disease in women, and the management of lipids in the elderly and dyslipidemia in children.

New Study on Thiazolidinediones May Show Benefits harmacology Watch In this Issue: Pioglitazone and heart disease; ARBs manufacturers spend millions to show the non-inferiority of their products compared to less expensive, generic ACE inhibitors; some athletes turn to growth hormone because it is difficult to detect; FDA Actions The thiazolidinediones rosiglitazone (Avandia) and pioglitazone (Actos) have taken their lumps in the last year, with evidence associating drugs with increased risks of heart failure.

c) Thiazolidinediones These drugs are used to improve effectiveness of insulin in fat tissues and muscle.

The drug was approved by FDA on April 28, 2005, and is indicated as adjunctive therapy to improve glycemic control in patients with Type 2 diabetes mellitus who are taking metformin, a sulfonylurea, a thiazolidinedione, a combination of metformin and a sulfonylurea, or a combination of metformin and a thiazolidinedione, but have not achieved adequate glycemic control.

Galvus received European Union approval in September 2007 for use in patients in combination with the anti-diabetes medicines metformin, thiazolidinedione (TZD) or a sulphonylurea (SU).